valproic acid has been researched along with Aggression in 107 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Aggression: Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 9.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode." | 9.11 | Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. ( Casey, DE; Citrome, L; Daniel, DG; Kochan, LD; Tracy, KA; Wozniak, P, 2004) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 8.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "Valproate and carbamazepine (CAR) have been proposed as adjunct alternatives for the control of aggression in psychiatric patients, although no definite conclusions have been reached." | 7.74 | Effects of sodium valproate and carbamazepine on food competition aggression in pigeons. ( Ahumada, M; Fachinelli, C; Fachinellizz, JM; Rodríguez-Echandía, EL; Torrecilla, M, 2007) |
| "Divalproex (DVP) and oxcarbazepine (OXC) are used to treat pediatric bipolar disorder (PBPD) with severe aggression but these agents have not been compared in head to head trials." | 7.73 | A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. ( Fleisher, CA; Gonzalez-Heydrich, J; Korndörfer, SR; MacMillan, CM; Mezzacappa, E; Rao, S, 2006) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 6.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "Valproic acid (VPA) is an effective drug, which is preferred for the treatments of epilepsy and various kinds of seizures." | 6.44 | The effects of valproic acid neurotoxicity on aggressive behavior in zebrafish autism model. ( Feng, T; Li, X; Lu, W, 2024) |
| "Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases." | 5.33 | Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006) |
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 5.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode." | 5.11 | Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. ( Casey, DE; Citrome, L; Daniel, DG; Kochan, LD; Tracy, KA; Wozniak, P, 2004) |
| "The objectives of this study were to determine whether autistic children taking levetiracetam (1) showed improvement in the areas of aggression, impulsivity, hyperkinesis, and mood instability, and (2) showed a nootropic response." | 5.10 | Levetiracetam in autistic children: an open-label study. ( Rugino, TA; Samsock, TC, 2002) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 4.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "To review and summarize the currently available data on the use of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate) in the treatment of behavioral and psychological symptoms of dementia (BPSD); to determine whether these medications can be recommended for routine clinical use." | 4.84 | Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. ( Konovalov, S; Muralee, S; Tampi, RR, 2008) |
| "Valproate (the active moiety of both valproic acid and divalproex sodium) is commonly used as an adjunctive agent for the treatment of schizophrenia." | 4.82 | Schizophrenia and valproate. ( Citrome, L, 2003) |
| "Valproate and carbamazepine (CAR) have been proposed as adjunct alternatives for the control of aggression in psychiatric patients, although no definite conclusions have been reached." | 3.74 | Effects of sodium valproate and carbamazepine on food competition aggression in pigeons. ( Ahumada, M; Fachinelli, C; Fachinellizz, JM; Rodríguez-Echandía, EL; Torrecilla, M, 2007) |
| "Divalproex (DVP) and oxcarbazepine (OXC) are used to treat pediatric bipolar disorder (PBPD) with severe aggression but these agents have not been compared in head to head trials." | 3.73 | A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. ( Fleisher, CA; Gonzalez-Heydrich, J; Korndörfer, SR; MacMillan, CM; Mezzacappa, E; Rao, S, 2006) |
| " The effects of apomorphine and sodium Di-n-propylacetate (DPA, sodium valproate) on pain-induced aggressive behavior were investigated in three inbred strains of mice: BALB/c, C57B1/6 and DBA/2, which exhibited spontaneously low levels of aggression." | 3.66 | Effects of apomorphine and sodium Di-n-propylacetate on the aggressive behaviour of three strains of mice. ( Allegra, SP; Mack, G; Mandel, P; Oliverio, A, 1979) |
| "Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study); https://www." | 3.01 | Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization. ( Bailey, BY; Blader, JC; Carlson, GA; Crowell, JA; Daviss, WB; Foley, CA; Kafantaris, V; Margulies, DM; Matthews, TL; Pliszka, SR; Sauder, C; Sinha, C, 2021) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 2.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "We recruited forty participants with Oppositional Defiant Disorder or Conduct Disorder." | 2.75 | Divalproex sodium-ER in outpatients with disruptive behavior disorders: a three month open label study. ( Delizonna, L; Hall, R; Mora, L; Saxena, K; Steiner, H; Torres, A; Torres, E, 2010) |
| " Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks." | 2.74 | Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. ( Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2009) |
| "The goal of this study was to determine if manifestations of agitation (ie, physical aggression, physically nonaggressive behavior, and verbally agitated behaviors) show different degrees of response to divalproex sodium (extended release or sprinkles) alone or in combination with second-generation antipsychotic agents." | 2.73 | Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. ( Adkison, L; Ahokpossi, C; Forester, B; Hyde, J; Perez, R; Sribney, W; Vanelli, M, 2007) |
| "New treatments for conduct disorder are sorely needed." | 2.71 | Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. ( Ford, S; Matthews, Z; Petersen, ML; Saxena, K; Steiner, H, 2003) |
| "Fifty-two outpatients with DSM-IV borderline personality disorder were randomly assigned to receive divalproex (N=20) or placebo (N=32), double-blind, for 12 weeks." | 2.71 | Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. ( Coccaro, EF; Hollander, E; Jiang, P; Smith, TB; Swann, AC, 2005) |
| "Borderline personality disorder is characterized by affective instability, impulsivity, and aggression and is associated with considerable morbidity and mortality." | 2.70 | A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. ( Allen, A; Bienstock, CA; Grossman, R; Hollander, E; Lopez, RP; Merkatz, L; Siever, LJ; Stein, DJ, 2001) |
| " Divalproex sodium was increased as tolerated using a flexible dosing schedule." | 2.69 | Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. ( Coccaro, EF; Kavoussi, RJ, 1998) |
| "Valproic acid (VPA) is an effective drug, which is preferred for the treatments of epilepsy and various kinds of seizures." | 2.44 | The effects of valproic acid neurotoxicity on aggressive behavior in zebrafish autism model. ( Feng, T; Li, X; Lu, W, 2024) |
| "Periorbital edema is a rare side effect of valproate." | 1.62 | Valproate-induced Periorbital Edema. ( Elhamamsy, S; Hatahet, S; Khalaf, K, 2021) |
| "Early treatment of epilepsy is warranted to avoid possible severe consequences." | 1.39 | Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle. ( Angeletti, G; Carbonetti, P; Del Casale, A; Fensore, C; Ferracuti, S; Girardi, P; Kotzalidis, GD; Lazanio, S; Muzi, A; Rapinesi, C; Savoja, V; Scatena, P; Serata, D; Tatarelli, R, 2013) |
| "These findings support that divalproex ER is an efficacious and well-tolerated pharmacologic agent for BPD, with the additional advantage of single daily dosing at bedtime." | 1.34 | An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. ( Baker, B; Braun, A; Chaplin, W; Hollander, E; Simeon, D, 2007) |
| " Chronic administration of the synthetic gonadotropin (luteinising hormone) releasing hormone analogue, goserelin, reduces testosterone activity." | 1.33 | Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. ( Raskind, MA; Rosin, RA, 2005) |
| "Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases." | 1.33 | Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006) |
| "In this study of patients with borderline personality disorder (BPD) or antisocial personality disorder (ASPD) hospitalized because of aggressive behavior, auditory and visual P300 evoked potentials were obtained prior to treatment with valproate." | 1.33 | Auditory and visual P300 evoked potentials do not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders. ( Patrick, G; Reeves, RR; Struve, FA, 2005) |
| "All patients met DSM-IV criteria for a disruptive behavior disorder (oppositional defiant disorder of conduct disorder) in addition to research criteria." | 1.32 | "Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder? ( Donovan, SJ; Jensen, PS; Klein, DF; Nunes, EV; Quitkin, FM; Ross, D; Stewart, JW, 2003) |
| "In this study of borderline and antisocial personality disorder patients hospitalized with aggressive behavior, EEGs were obtained prior to treatment with valproate." | 1.32 | EEG does not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders. ( Patrick, G; Reeves, RR; Struve, FA, 2003) |
| " The patient's regular physicians managed all treatment decisions, including decisions on dosage and plasma level measurements of sodium valproate and decisions regarding discontinuation." | 1.32 | Sodium valproate in aggressive behaviour in dementia: a twelve-week open label follow-up study. ( Duivenvoorden, HJ; Duursma, SA; Eikelenboom, P; Haffmans, PM; Jansen, PA; Sival, RC, 2004) |
| "A diagnosis of Alzheimer's disease was made." | 1.29 | [Case report of sodium valproate treatment of aggression associated with Alzheimer's disease]. ( Akagi, M; Takahashi, M, 1996) |
| "Muscimol was effective in the first session but did not differ significantly from saline in the second and third session." | 1.26 | Effects of sodium n-dipropylacetate, muscimol hydrobromide and (R,S) nipecotic acid amide on isolation-induced aggressive behavior in mice. ( Mandel, P; Puglisi-Allegra, S, 1980) |
| "A residual effect of DPA against seizures induced by pentetrazole was shown, i." | 1.26 | Anticonvulsant and antiaggressive properties of di-n-propyl acetate after repeated treatment. ( Ciesielski, L; Klein, M; Mandel, P; Simler, S, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (12.15) | 18.7374 |
| 1990's | 18 (16.82) | 18.2507 |
| 2000's | 49 (45.79) | 29.6817 |
| 2010's | 20 (18.69) | 24.3611 |
| 2020's | 7 (6.54) | 2.80 |
| Authors | Studies |
|---|---|
| Hatahet, S | 1 |
| Khalaf, K | 1 |
| Elhamamsy, S | 1 |
| Li, X | 1 |
| Feng, T | 1 |
| Lu, W | 1 |
| Blader, JC | 2 |
| Pliszka, SR | 2 |
| Kafantaris, V | 2 |
| Foley, CA | 1 |
| Carlson, GA | 1 |
| Crowell, JA | 1 |
| Bailey, BY | 1 |
| Sauder, C | 1 |
| Daviss, WB | 1 |
| Sinha, C | 1 |
| Matthews, TL | 1 |
| Margulies, DM | 1 |
| Abulseoud, OA | 1 |
| Şenormancı, G | 1 |
| Şenormancı, Ö | 1 |
| Güçlü, O | 1 |
| Schleyer, B | 1 |
| Camsari, U | 1 |
| Cortese, S | 1 |
| Novins, DK | 1 |
| Colijn, MA | 1 |
| Lee, TJ | 1 |
| Zanello, AF | 1 |
| Morrison, TR | 1 |
| Ricci, LA | 1 |
| Melloni, RH | 1 |
| Whiting, WL | 1 |
| Velasco, R | 1 |
| Stewart, JT | 2 |
| Ostinelli, EG | 1 |
| Hussein, M | 1 |
| Ahmed, U | 1 |
| Rehman, FU | 1 |
| Miramontes, K | 1 |
| Adams, CE | 1 |
| Silva, EF | 1 |
| Silva, AI | 1 |
| Asth, L | 2 |
| Souza, LS | 1 |
| Zaveri, NT | 1 |
| Guerrini, R | 2 |
| Calo', G | 1 |
| Ruzza, C | 2 |
| Gavioli, EC | 2 |
| Baillon, SF | 1 |
| Narayana, U | 1 |
| Luxenberg, JS | 1 |
| Clifton, AV | 1 |
| Sailer, L | 1 |
| Duclot, F | 1 |
| Wang, Z | 1 |
| Kabbaj, M | 1 |
| Connolly, S | 1 |
| Caldwell, SB | 1 |
| Wilson, FC | 1 |
| Zarghami, M | 1 |
| Sheikhmoonesi, F | 1 |
| Ala, S | 1 |
| Yazdani, J | 1 |
| Farnia, S | 1 |
| Rapinesi, C | 1 |
| Del Casale, A | 1 |
| Serata, D | 1 |
| Kotzalidis, GD | 1 |
| Scatena, P | 1 |
| Muzi, A | 1 |
| Lazanio, S | 1 |
| Savoja, V | 1 |
| Carbonetti, P | 1 |
| Fensore, C | 1 |
| Ferracuti, S | 1 |
| Angeletti, G | 1 |
| Tatarelli, R | 1 |
| Girardi, P | 1 |
| Budhdeo, S | 1 |
| Marquette, M | 1 |
| Singh, D | 1 |
| Rajagopal, V | 1 |
| Barnhorst, A | 1 |
| Xiong, GL | 1 |
| Trapella, C | 1 |
| Coccaro, EF | 4 |
| Lee, R | 1 |
| Breen, EC | 1 |
| Irwin, MR | 1 |
| Avari, JM | 1 |
| Nolan, KA | 2 |
| Shope, CB | 2 |
| Citrome, L | 4 |
| Volavka, J | 2 |
| Schooler, NR | 1 |
| Jensen, PS | 2 |
| Steiner, H | 5 |
| Karnik, NS | 1 |
| Saxena, K | 4 |
| Mora, L | 1 |
| Torres, E | 1 |
| Hall, R | 1 |
| Delizonna, L | 1 |
| Torres, A | 1 |
| Smagin, DA | 1 |
| Bondar', NP | 1 |
| Kudriavtseva, NN | 1 |
| Mizukami, K | 1 |
| Hatanaka, K | 1 |
| Ishii, T | 1 |
| Iwakiri, M | 1 |
| Sodeyama, N | 1 |
| Tanaka, Y | 1 |
| Asada, T | 1 |
| Poetter, CE | 1 |
| Padhy, R | 1 |
| Remsing, L | 1 |
| Huemer, J | 1 |
| Plattner, B | 1 |
| West, AE | 1 |
| Weinstein, SM | 1 |
| Celio, CI | 1 |
| Henry, D | 1 |
| Pavuluri, MN | 1 |
| Levy, T | 1 |
| Bloch, Y | 1 |
| Sival, RC | 2 |
| Haffmans, PM | 2 |
| Jansen, PA | 2 |
| Duursma, SA | 2 |
| Eikelenboom, P | 2 |
| Rugino, TA | 1 |
| Samsock, TC | 1 |
| Hollander, E | 4 |
| Tracy, KA | 2 |
| Swann, AC | 3 |
| McElroy, SL | 1 |
| Wozniak, P | 2 |
| Sommerville, KW | 1 |
| Nemeroff, CB | 1 |
| Reeves, RR | 2 |
| Struve, FA | 2 |
| Patrick, G | 2 |
| Donovan, SJ | 2 |
| Nunes, EV | 2 |
| Stewart, JW | 2 |
| Ross, D | 1 |
| Quitkin, FM | 2 |
| Klein, DF | 2 |
| Petersen, ML | 1 |
| Ford, S | 1 |
| Matthews, Z | 1 |
| Vance, H | 1 |
| Kauffman, C | 1 |
| Miller, B | 1 |
| Mansour, T | 1 |
| Coffey, B | 1 |
| Casey, DE | 1 |
| Daniel, DG | 1 |
| Kochan, LD | 1 |
| Duivenvoorden, HJ | 1 |
| Yehya, N | 1 |
| Saldarini, CT | 1 |
| Koski, ME | 1 |
| Davanzo, P | 1 |
| DelBello, MP | 2 |
| Adler, C | 1 |
| Strakowski, SM | 2 |
| Cummings, MR | 1 |
| Miller, BD | 1 |
| Pinna, G | 2 |
| Agis-Balboa, RC | 1 |
| Doueiri, MS | 2 |
| Guidotti, A | 2 |
| Costa, E | 2 |
| Stanford, MS | 1 |
| Helfritz, LE | 1 |
| Conklin, SM | 1 |
| Villemarette-Pittman, NR | 1 |
| Greve, KW | 1 |
| Adams, D | 1 |
| Houston, RJ | 1 |
| Tremolizzo, L | 1 |
| Dong, E | 1 |
| Grayson, DR | 1 |
| Davis, J | 1 |
| Tueting, P | 1 |
| Rodriguez-Menendez, V | 1 |
| Jiang, P | 1 |
| Smith, TB | 1 |
| Hellings, JA | 2 |
| Nickel, EJ | 2 |
| Weckbaugh, M | 2 |
| McCarter, K | 1 |
| Mosier, M | 1 |
| Schroeder, SR | 2 |
| Chungh, DS | 1 |
| Kim, BN | 1 |
| Cho, SC | 1 |
| Rosin, RA | 1 |
| Raskind, MA | 2 |
| Barzman, DH | 3 |
| McConville, BJ | 1 |
| Masterson, B | 1 |
| McElroy, S | 1 |
| Sethuraman, G | 1 |
| Moore, K | 1 |
| Kahwaty, AM | 1 |
| Nelson, D | 1 |
| Cain, SE | 1 |
| Zarcone, JR | 1 |
| Reese, RM | 1 |
| Hall, S | 1 |
| Ermer, DJ | 1 |
| Tsai, LY | 1 |
| Cook, EH | 1 |
| Kratochvil, CJ | 1 |
| Varley, C | 1 |
| Cummins, TK | 1 |
| Martin, A | 1 |
| Sugden, SG | 1 |
| Kile, SJ | 1 |
| Farrimond, DD | 1 |
| Hilty, DM | 2 |
| Bourgeois, JA | 1 |
| Howe, M | 1 |
| Simeonova, D | 1 |
| Chang, K | 1 |
| MacMillan, CM | 1 |
| Korndörfer, SR | 1 |
| Rao, S | 1 |
| Fleisher, CA | 1 |
| Mezzacappa, E | 1 |
| Gonzalez-Heydrich, J | 1 |
| Gobbi, G | 1 |
| Gaudreau, PO | 1 |
| Leblanc, N | 1 |
| Herrmann, N | 1 |
| Lanctôt, KL | 1 |
| Rothenburg, LS | 1 |
| Eryavec, G | 1 |
| Adler, CM | 1 |
| Stanford, KE | 1 |
| Buckley, PF | 1 |
| Paulsson, B | 1 |
| Brecher, M | 1 |
| Simeon, D | 1 |
| Baker, B | 1 |
| Chaplin, W | 1 |
| Braun, A | 1 |
| Fachinelli, C | 1 |
| Ahumada, M | 1 |
| Fachinellizz, JM | 1 |
| Torrecilla, M | 1 |
| Rodríguez-Echandía, EL | 1 |
| Qalbani, M | 1 |
| De León, OA | 1 |
| Czobor, P | 1 |
| Forester, B | 1 |
| Vanelli, M | 1 |
| Hyde, J | 1 |
| Perez, R | 1 |
| Ahokpossi, C | 1 |
| Sribney, W | 1 |
| Adkison, L | 1 |
| Konovalov, S | 1 |
| Muralee, S | 1 |
| Tampi, RR | 1 |
| Findling, RL | 1 |
| Simler, S | 5 |
| Puglisi-Allegra, S | 3 |
| Mandel, P | 8 |
| Depaulis, A | 2 |
| Vergnes, M | 1 |
| Haug, M | 1 |
| Kim, L | 1 |
| Kempf, E | 2 |
| Ciesielski, L | 3 |
| Klein, M | 1 |
| Sulcová, A | 1 |
| Krsiak, M | 1 |
| Masek, K | 1 |
| Rodgers, RJ | 1 |
| Horne, M | 1 |
| Lindley, SE | 1 |
| Geracioti, TD | 1 |
| Wilcox, J | 1 |
| Bhatara, VS | 1 |
| Carrera, J | 1 |
| Zayas, EM | 1 |
| Grossberg, GT | 1 |
| Takahashi, M | 1 |
| Akagi, M | 1 |
| Wroblewski, BA | 1 |
| Joseph, AB | 1 |
| Kupfer, J | 1 |
| Kalliel, K | 1 |
| Susser, ES | 1 |
| Steele, M | 1 |
| Fisman, S | 1 |
| Haas, S | 1 |
| Vincent, K | 1 |
| Holt, J | 1 |
| Lippmann, S | 2 |
| Rodriguez, GD | 1 |
| Hales, RE | 1 |
| Kavoussi, RJ | 1 |
| Ruedrich, S | 1 |
| Swales, TP | 1 |
| Fossaceca, C | 1 |
| Toliver, J | 1 |
| Rutkowski, A | 1 |
| Lindenmayer, JP | 1 |
| Kotsaftis, A | 1 |
| Buchalter, EN | 1 |
| Lantz, MS | 1 |
| Allen, A | 1 |
| Lopez, RP | 1 |
| Bienstock, CA | 1 |
| Grossman, R | 1 |
| Siever, LJ | 1 |
| Merkatz, L | 1 |
| Stein, DJ | 1 |
| van Wattum, PJ | 1 |
| Afaq, I | 1 |
| Riaz, J | 1 |
| Sedky, K | 1 |
| Chung, DJ | 1 |
| Vanina, Y | 1 |
| el-Mallakh, R | 1 |
| Iijima, M | 1 |
| Frankenburg, FR | 1 |
| Zanarini, MC | 1 |
| Allegra, SP | 1 |
| Mack, G | 2 |
| Oliverio, A | 1 |
| Ruuskanen, I | 1 |
| Kilpeläinen, HO | 1 |
| Riekkinen, PJ | 1 |
| Maitre, M | 1 |
| Mazure, CM | 1 |
| Druss, BG | 1 |
| Cellar, JS | 1 |
| Mattes, JA | 1 |
| Szymanski, HV | 1 |
| Olympia, J | 1 |
| Molina, V | 1 |
| Gobaille, S | 1 |
| Oehler, J | 1 |
| Jähkel, M | 1 |
| Schmidt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD[NCT00794625] | Phase 4 | 270 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder[NCT00228046] | Phase 4 | 40 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility[NCT00308360] | Phase 4 | 46 participants | Interventional | 1999-09-30 | Completed | ||
| Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression: A 42-Day, Single-Site, Forced-Titration, Parallel Group, Randomized, Double-Blind, Placebo Controlled Trial[NCT00621751] | 70 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 2.9 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.3 |
| Placebo | 3.1 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: Day-42
| Intervention | score on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 3.1 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, the primary outcome was a composite measure of observer-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., observer-rated NPI-I/A Rasch construct scores). Mean day-42 observer-rated NPI-I/A Rasch construct scores were compared between placebo vs. carbamazepine using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: 42 days
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.7 |
| Placebo | 36.7 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, a composite measure of participant-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., participant-rated NPI-I/A Rasch construct scores). Mean day-42 participant-rated NPI-I/A Rasch construct scores were compared between placebo vs. CBZ using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: Day 42
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.5 |
| Placebo | 36.4 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Observer. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: 42-day
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 20 |
| Placebo | 26 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Participant. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: Day-42
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 21 |
| Placebo | 16 |
12 reviews available for valproic acid and Aggression
| Article | Year |
|---|---|
The characterization of psychotic symptoms in succinic semialdehyde dehydrogenase deficiency: a review.
Topics: Adolescent; Age of Onset; Aggression; Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Anxiety | 2020 |
Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Carbamazepine; Humans; Oxcarbazepine; Psycho | 2018 |
Valproate preparations for agitation in dementia.
Topics: Aged; Aggression; Antimanic Agents; Cognition; Dementia; Humans; Psychomotor Agitation; Randomized C | 2018 |
[Pharmacotherapy for conduct disorder in children and adolescents].
Topics: Adolescent; Aggression; Anticoagulants; Antimanic Agents; Antipsychotic Agents; Attention Deficit Di | 2012 |
Schizophrenia and valproate.
Topics: Affect; Aggression; Antimanic Agents; Clinical Trials as Topic; Humans; Schizophrenia; Schizophrenic | 2003 |
Pharmacologic management of behavioral instability in medically ill pediatric patients.
Topics: Adolescent; Adrenergic alpha-Agonists; Aggression; Analgesics, Non-Narcotic; Behavior Therapy; Behav | 2004 |
Brain neurosteroids in gender-related aggression induced by social isolation.
Topics: Aggression; Animals; Female; GABA Agents; Gonadal Steroid Hormones; Male; Methionine; Mice; Neurotra | 2004 |
Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review.
Topics: Aggression; Amines; Anticonvulsants; Carbamazepine; Cognition Disorders; Cyclohexanecarboxylic Acids | 2008 |
Pharmacological treatment of pathologic aggression in children.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Central Nervous System Stimulants; Child; Drug Pr | 2008 |
Treatment of aggression in patients with bipolar disorder.
Topics: Aggression; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Combined Modality Therapy; Drug T | 1999 |
Evaluation and management of aggressive behavior in the elderly demented patient.
Topics: Age Factors; Aged; Aggression; Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Cholinergic | 1999 |
Use of sodium valproate in violent and aggressive behaviors: a critical review.
Topics: Adolescent; Adult; Aged; Aggression; Anticonvulsants; Antimanic Agents; Child; Clinical Trials as To | 2000 |
29 trials available for valproic acid and Aggression
| Article | Year |
|---|---|
Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
A comparative study of beneficial effects of Olanzapine and sodium valproate on aggressive behavior of patients who are on methadone maintenance therapy: a randomized triple blind clinical trial.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Female; GABA Agents; Heroin Dependence; Hu | 2013 |
Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder.
Topics: Adult; Aggression; Biomarkers; C-Reactive Protein; Disruptive, Impulse Control, and Conduct Disorder | 2015 |
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
Topics: Adolescent; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Atten | 2009 |
Divalproex sodium-ER in outpatients with disruptive behavior disorders: a three month open label study.
Topics: Adolescent; Aggression; Attention Deficit and Disruptive Behavior Disorders; Child; Female; GABA Age | 2010 |
Symptomatic response to divalproex in subtypes of conduct disorder.
Topics: Adolescent; Aggression; Antimanic Agents; Conduct Disorder; Double-Blind Method; Humans; Male; Self | 2011 |
Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2011 |
Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial.
Topics: Aged; Aged, 80 and over; Aggression; Antimanic Agents; Cross-Over Studies; Dementia; Double-Blind Me | 2002 |
Levetiracetam in autistic children: an open-label study.
Topics: Aggression; Anticonvulsants; Autistic Disorder; Cetirizine; Child; Child Behavior Disorders; Child, | 2002 |
Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders.
Topics: Adult; Aged; Aggression; Analysis of Variance; Chi-Square Distribution; Double-Blind Method; Female; | 2003 |
Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial.
Topics: Adolescent; Aggression; Anger; Anticonvulsants; Arousal; Conduct Disorder; Crime; Dose-Response Rela | 2003 |
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; H | 2004 |
Divalproex for the treatment of aggression associated with adolescent mania.
Topics: Adolescent; Aggression; Antimanic Agents; Bipolar Disorder; Child; Humans; Psychiatric Status Rating | 2004 |
A comparison of anticonvulsants in the treatment of impulsive aggression.
Topics: Adult; Aggression; Anticonvulsants; Carbamazepine; Double-Blind Method; Female; Humans; Impulsive Be | 2005 |
Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
Topics: Adult; Age of Onset; Aggression; Anticonvulsants; Borderline Personality Disorder; Double-Blind Meth | 2005 |
The overt aggression scale for rating aggression in outpatient youth with autistic disorder: preliminary findings.
Topics: Adolescent; Adult; Aggression; Ambulatory Care; Autistic Disorder; Child; Double-Blind Method; Femal | 2005 |
A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders.
Topics: Adolescent; Adult; Aggression; Anticonvulsants; Child; Child Development Disorders, Pervasive; Doubl | 2005 |
Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder.
Topics: Adolescent; Affect; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorder | 2006 |
A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anticonvulsants; Cognition Disorders; Double | 2007 |
The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2006 |
Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Diarrhea; Drug Therapy, Combination; Femal | 2007 |
Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Topics: Aged; Aged, 80 and over; Aggression; Antimanic Agents; Antipsychotic Agents; Behavioral Symptoms; De | 2007 |
Divalproex sodium in the treatment of aggressive behavior.
Topics: Adult; Aggression; Bipolar Disorder; Borderline Personality Disorder; Case-Control Studies; Female; | 1994 |
Divalproex treatment of disruptive adolescents: a report of 10 cases.
Topics: Adolescent; Adolescent Behavior; Aggression; Ambulatory Care; Attention Deficit Disorder with Hypera | 1997 |
Divalproex: a possible treatment alternative for demented, elderly aggressive patients.
Topics: Aged; Aged, 80 and over; Aggression; Dementia; Female; GABA Agents; Geriatric Psychiatry; Humans; Lo | 1997 |
Divalproex sodium for impulsive aggressive behavior in patients with personality disorder.
Topics: Adult; Aggression; Anticonvulsants; Antimanic Agents; Female; Fluoxetine; Humans; Impulsive Behavior | 1998 |
Effect of divalproex sodium on aggression and self-injurious behaviour in adults with intellectual disability: a retrospective review.
Topics: Adult; Aggression; Female; GABA Agents; Humans; Intellectual Disability; Male; Middle Aged; Retrospe | 1999 |
A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.
Topics: Adolescent; Adult; Aggression; Ambulatory Care; Anticonvulsants; Borderline Personality Disorder; Co | 2001 |
Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.
Topics: Adult; Aggression; Anger; Anticonvulsants; Bipolar Disorder; Borderline Personality Disorder; Comorb | 2002 |
66 other studies available for valproic acid and Aggression
| Article | Year |
|---|---|
Valproate-induced Periorbital Edema.
Topics: Aged; Aggression; Alzheimer Disease; Edema; Humans; Male; Valproic Acid | 2021 |
The effects of valproic acid neurotoxicity on aggressive behavior in zebrafish autism model.
Topics: Aggression; Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, | 2024 |
Sex difference in the progression of manic symptoms during acute hospitalization: A prospective pilot study.
Topics: Adult; Aggression; Antimanic Agents; Bipolar Disorder; Disease Progression; Female; Follow-Up Studie | 2020 |
Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2021 |
Valproate selectively suppresses adolescent anabolic/androgenic steroid-induced aggressive behavior: implications for a role of hypothalamic γ-aminobutyric acid neural signaling.
Topics: Adolescent; Aggression; Androgens; Animals; Anticonvulsants; Behavior Control; Behavior, Animal; Dos | 2021 |
Treatment of Behavioral Disinhibition in Huntington's Disease With Valproic Acid.
Topics: Aggression; Anticonvulsants; Female; Humans; Huntington Disease; Middle Aged; Problem Behavior; Valp | 2018 |
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.
Topics: Aggression; Agonistic Behavior; Animals; Anxiety; Bipolar Disorder; Carbamazepine; Cycloheptanes; De | 2019 |
Consequences of prenatal exposure to valproic acid in the socially monogamous prairie voles.
Topics: Aggression; Animals; Anxiety; Arvicolinae; Behavior, Animal; Female; Gene Expression Regulation, Dev | 2019 |
Maintaining community living with post brain injury agitation: a role for sodium valproate.
Topics: Adult; Aggression; Antipsychotic Agents; Aphasia; Brain Injuries; Community Integration; Humans; Mal | 2013 |
Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle.
Topics: Accidents, Traffic; Aggression; Amines; Anterior Temporal Lobectomy; Anticonvulsants; Brain Injuries | 2013 |
Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?
Topics: Aged; Aggression; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Brain Diseases; Confusion; Delusi | 2014 |
Pulmonary embolism in a psychiatric patient.
Topics: Adult; Aggression; Antipsychotic Agents; Autopsy; Benzodiazepines; Bipolar Disorder; Catatonia; Deat | 2014 |
Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor.
Topics: Aggression; Animals; Central Nervous System Agents; Dose-Response Relationship, Drug; Male; Mice; Mi | 2015 |
Paradoxical Agitation in Adolescent Male on Valproate.
Topics: Adolescent; Aggression; Akathisia, Drug-Induced; Antimanic Agents; Antipsychotic Agents; Humans; Irr | 2016 |
Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study.
Topics: Adult; Aggression; Antimanic Agents; Attitude of Health Personnel; Attitude to Health; Cohort Studie | 2009 |
Integrated treatment of aggression in the context of ADHD in children refractory to stimulant monotherapy: a window into the future of child psychopharmacology.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2009 |
[Effect of sodium valproate on aggressive behavior of male mice with various aggression experience].
Topics: Aggression; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred C5 | 2010 |
Effects of sodium valproate on behavioral disturbances in elderly outpatients with dementia.
Topics: Aged; Aged, 80 and over; Aggression; Antimanic Agents; Dementia; Dose-Response Relationship, Drug; F | 2010 |
Treatment of taunting behavior in vascular dementia with valproic acid.
Topics: Aged, 80 and over; Aggression; Antimanic Agents; Dementia, Vascular; Humans; Male; Valproic Acid | 2011 |
EEG does not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders.
Topics: Adult; Aggression; Anticonvulsants; Antisocial Personality Disorder; Borderline Personality Disorder | 2003 |
"Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder?
Topics: Adolescent; Adult; Age Factors; Aggression; Anticonvulsants; Attention Deficit and Disruptive Behavi | 2003 |
Treatment of agitation using Depakote: a patient with dementia.
Topics: Affect; Aggression; Alzheimer Disease; Anxiety; Cooperative Behavior; Dose-Response Relationship, Dr | 2003 |
Clinical case presentation: therapeutic challenges in adolescent-onset bipolar disorder.
Topics: Adolescent; Aggression; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorde | 2003 |
Sodium valproate in aggressive behaviour in dementia: a twelve-week open label follow-up study.
Topics: Aged; Aged, 80 and over; Aggression; Analysis of Variance; Antimanic Agents; Dementia; Drug Administ | 2004 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Aggression; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; Child; Diagnosis, | 2004 |
Auditory and visual P300 evoked potentials do not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders.
Topics: Adult; Aggression; Anticonvulsants; Antisocial Personality Disorder; Borderline Personality Disorder | 2005 |
Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice.
Topics: Aggression; Animals; Anticonvulsants; Behavior, Animal; Benzodiazepines; Blotting, Western; Cell Adh | 2005 |
Neuroleptic malignant syndrome due to three atypical antipsychotics in a child.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Temperature; Child; Dibenz | 2005 |
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
Topics: Aged; Aggression; Alzheimer Disease; Amines; Antipsychotic Agents; Benzodiazepines; Cyclohexanecarbo | 2005 |
Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype?
Topics: Adolescent; Aggression; Antimanic Agents; Bipolar Disorder; Child; Female; Humans; Impulsive Behavio | 2005 |
Less is more: inpatient management of a child with complex pharmacotherapy.
Topics: Aggression; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Depressio | 2006 |
Pharmacological intervention for cognitive deficits and aggression in frontal lobe injury.
Topics: Adult; Aggression; Amantadine; Cognition Disorders; Conduct Disorder; Donepezil; Frontal Lobe; Human | 2006 |
A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Child; Drug A | 2006 |
Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; Dr | 2006 |
Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
Topics: Adult; Aggression; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials, Phase | 2007 |
An open-label trial of divalproex extended-release in the treatment of borderline personality disorder.
Topics: Adult; Aggression; Anticonvulsants; Borderline Personality Disorder; Delayed-Action Preparations; Fe | 2007 |
Effects of sodium valproate and carbamazepine on food competition aggression in pigeons.
Topics: Aggression; Animals; Antimanic Agents; Carbamazepine; Columbidae; Competitive Behavior; Feeding Beha | 2007 |
Intravenous valproate treatment of uncontrollable aggression: a case report.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationshi | 2007 |
Effects of n-di-propylacetate on aggressive behavior and brain GABA level in isolated mice.
Topics: Aggression; Animals; Brain; gamma-Aminobutyric Acid; Humans; Kinetics; Male; Mice; Mice, Inbred DBA; | 1983 |
Gabaergic modulation of mouse-killing in the rat.
Topics: Aggression; Aminocaproates; Animals; GABA Antagonists; gamma-Aminobutyric Acid; Humans; Isoxazoles; | 1984 |
Studies on the involvement of GABA in the aggression directed by groups of intact or gonadectomized male and female mice towards lactating intruders.
Topics: Aggression; Animals; Brain Chemistry; Castration; Dose-Response Relationship, Drug; Female; gamma-Am | 1980 |
Effects of sodium n-dipropylacetate, muscimol hydrobromide and (R,S) nipecotic acid amide on isolation-induced aggressive behavior in mice.
Topics: Aggression; Animals; gamma-Aminobutyric Acid; Humans; Male; Mice; Motor Activity; Muscimol; Nipecoti | 1980 |
Involvement of the GABAergic system on shock-induced aggressive behavior in two strains of mice.
Topics: 4-Aminobutyrate Transaminase; Aggression; Allylglycine; Animals; Brain Chemistry; Dose-Response Rela | 1981 |
Anticonvulsant and antiaggressive properties of di-n-propyl acetate after repeated treatment.
Topics: Acoustic Stimulation; Aggression; Animals; Anticonvulsants; Brain; Female; gamma-Aminobutyric Acid; | 1982 |
Effects of calcium valproate and aminooxyacetic acid on agonistic behaviour in mice.
Topics: Acetates; Aggression; Agonistic Behavior; Aminooxyacetic Acid; Animals; Humans; Male; Mice; Valproic | 1981 |
GABAergic influences on defensive fighting in rats.
Topics: Aggression; Aminocaproates; Animals; Baclofen; Bicuculline; Electroshock; gamma-Aminobutyric Acid; H | 1982 |
Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes.
Topics: Adult; Aged; Aged, 80 and over; Aggression; Anger; Depression; Humans; Middle Aged; Neurocognitive D | 1995 |
Valproic acid treatment of episodic explosiveness related to brain injury.
Topics: Adolescent; Aggression; Brain Injuries; Humans; Male; Neurocognitive Disorders; Valproic Acid | 1994 |
Medications for aggressiveness.
Topics: Aggression; Carbamazepine; Child; Child Behavior Disorders; Clonidine; Electroencephalography; Hallu | 1994 |
Treating the agitated Alzheimer patient.
Topics: Adrenergic beta-Antagonists; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Buspirone; C | 1996 |
[Case report of sodium valproate treatment of aggression associated with Alzheimer's disease].
Topics: Aged; Aggression; Alzheimer Disease; Anticonvulsants; Humans; Male; Valproic Acid | 1996 |
Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury.
Topics: Activities of Daily Living; Adult; Aggression; Anticonvulsants; Brain Concussion; Brain Damage, Chro | 1997 |
Bipolar disorder in children and adolescents: current challenges.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Clom | 1997 |
Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders.
Topics: Aggression; Anticonvulsants; Autistic Disorder; Child; Female; Humans; Infusions, Intravenous; Psych | 1998 |
Treatment of impulsivity and aggression in a patient with vascular dementia.
Topics: Aged; Aggression; Antimanic Agents; Dementia, Vascular; Disruptive, Impulse Control, and Conduct Dis | 2001 |
Valproic acid and risperidone.
Topics: Aggression; Antipsychotic Agents; Child; Child Behavior Disorders; Dose-Response Relationship, Drug; | 2001 |
Divalproex as a calmative adjunct for aggressive schizophrenic patients.
Topics: Adult; Aggression; Antipsychotic Agents; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; | 2002 |
Valproate-induced parkinsonism in a demented elderly patient.
Topics: Aged; Aggression; Alzheimer Disease; Humans; Male; Parkinsonian Disorders; Valproic Acid; Violence | 2002 |
Effects of apomorphine and sodium Di-n-propylacetate on the aggressive behaviour of three strains of mice.
Topics: Aggression; Animals; Apomorphine; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred | 1979 |
Side effects of sodium valproate during long-term treatment in epilepsy.
Topics: Adolescent; Adult; Aggression; Brain; Epilepsy; Female; Humans; Male; Middle Aged; Time Factors; Val | 1979 |
Involvement of central GABA-ergic systems in convulsions and aggressive behavior.
Topics: 4-Aminobutyrate Transaminase; Aggression; Allylglycine; Animals; Bicuculline; Brain; Fatty Acids; ga | 1979 |
Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol.
Topics: Age Factors; Aged; Aggression; Comorbidity; Drug Therapy, Combination; Female; Humans; Neurocognitiv | 1992 |
Valproic acid for nonaffective aggression in the mentally retarded.
Topics: Adult; Affect; Aggression; Animals; Female; gamma-Aminobutyric Acid; Humans; Intellectual Disability | 1992 |
Divalproex in posttraumatic stress disorder.
Topics: Adult; Aggression; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Stress Disorder | 1991 |
Effects of the potentiation of the GABAergic neurotransmission in the olfactory bulbs on mouse-killing behavior.
Topics: Aggression; Aminocaproates; Animals; Brain Chemistry; Drug Synergism; gamma-Aminobutyric Acid; Isoni | 1986 |
[Effect of lithium, carbamazepine, ca-valproate and diazepam on changes in social isolation-induced behavior in mice].
Topics: Aggression; Animals; Behavior, Animal; Carbamazepine; Diazepam; Lithium; Male; Mice; Motor Activity; | 1985 |